Secukinumab Reduces Psoriasis-associated Pruritus and Regenerates the Cutaneous Nerve Architecture: Results from PSORITUS a Doubleblind, Placebo-controlled, Randomized Withdrawal Phase IIIb Study

• Main Authors: Lina Renkhold (Author), Manuel P. Pereira (Author), Karin Loser (Author), Dieter Metze (Author), Daniel Baeumer (Author), Nima Melzer (Author), Maximilian Reinhardt (Author), Athanasios Tsianakas (Author), Thomas Luger (Author), Christian Mess (Author), Ruth Becker (Author), Clara Hambüchen (Author), Konstantin Agelopoulos (Author), Sonja Ständer (Author)
• Format: Book
• Published: Medical Journals Sweden, 2024-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The occurrence of pruritus in psoriasis was previously underestimated but is a significant burden. Secukinumab (SEC), a monoclonal anti-interleukin-17A antibody, efficiently controls signs of psoriasis, but the effect on pruritus and cutaneous neuroanatomy remained unknown. The primary objective of...